NCT05638880View on ClinicalTrials.gov

Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

December 20, 2025

Study Completion Date

October 20, 2026

Conditions
Diabetic Nephropathies
Interventions
DRUG

Valsartan 80 mg

Valsartan is an angiotensin receptor blocker.

DRUG

Empagliflozin 10 MG

Empagliflozin is an oral hypoglycemic drug.

DRUG

Levocetirizine

Levocetirizine, Histamine-1 receptor antagonists provide a highly successful approach for controlling allergic and inflammatory conditions

Trial Locations (1)

315511

RECRUITING

Mansoura University, Al Mansurah

All Listed Sponsors
collaborator

Tanta University

OTHER

lead

Mostafa Bahaa

OTHER